{"id":118993,"date":"2025-01-23T00:00:00","date_gmt":"2025-01-23T00:00:00","guid":{"rendered":"https:\/\/medgoo.com\/index.php\/2025\/01\/23\/perioperative-chemo-with-flot-ups-survival-in-resectable-esophageal-cancer\/"},"modified":"2025-01-27T16:10:28","modified_gmt":"2025-01-27T16:10:28","slug":"perioperative-chemo-with-flot-ups-survival-in-resectable-esophageal-cancer","status":"publish","type":"post","link":"https:\/\/medgoo.com\/index.php\/2025\/01\/23\/perioperative-chemo-with-flot-ups-survival-in-resectable-esophageal-cancer\/","title":{"rendered":"Perioperative Chemo With FLOT Ups Survival in Resectable Esophageal Cancer"},"content":{"rendered":"<h3>\n<p>Improved survival seen with perioperative chemotherapy with FLOT versus preoperative chemoradiotherapy<\/p>\n<\/h3>\n<p><b>By Elana Gotkine HealthDay Reporter<\/b><br \/>\n<b><\/b><\/p>\n<p>THURSDAY, Jan. 23, 2025 (HealthDay News) &#8212; For patients with resectable esophageal adenocarcinoma, perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) leads to improved survival compared with preoperative chemoradiotherapy, according to a study published in the Jan. 23 issue of the <em>New England Journal of Medicine<\/em>.<\/p>\n<p>Jens Hoeppner, M.D., from Bielefeld University in Detmold, Germany, and colleagues conducted a phase 3 multicenter trial involving patients with resectable esophageal adenocarcinoma who were randomly assigned to receive perioperative chemotherapy with FLOT plus surgery or preoperative chemoradiotherapy (radiotherapy at a dose of 41.4 Gy and carboplatin and paclitaxel) plus surgery (221 and 217 patients, respectively). Eligibility criteria included a primary tumor with clinical stage cT1 cN+, cT2-4a cN+, or cT2-4a cN0 disease. The primary end point was overall survival.<\/p>\n<p>The researchers found that overall survival at three years was 57.4 and 50.7 percent in the FLOT and preoperative-chemoradiotherapy groups, respectively, with a median follow-up of 55 months (hazard ratio for death, 0.70). At three years, progression-free survival was 51.6 and 35.0 percent in the FLOT and preoperative-chemoradiotherapy groups, respectively (hazard ratio for disease progression or death, 0.66). Among the patients who started the assigned treatment, grade 3 or higher adverse events occurred in 58.0 and 50.0 percent of those in the FLOT and preoperative-chemoradiotherapy groups, respectively.<\/p>\n<p>&#8220;The current trial showed superior overall survival with FLOT as compared with preoperative chemoradiotherapy, with a median overall survival of 66 and 37 months, respectively,&#8221; the authors write.<\/p>\n<p><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2409408\">Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n<p><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMe2415379\">Editorial (subscription or payment may be required)<\/a><\/p>\n<p><i><\/i><br \/>\n<i>Copyright &#169; 2025 <a href=\"https:\/\/consumer.healthday.com\/\" target=\"_new\" rel=\"noopener\">HealthDay<\/a>. All rights reserved.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Improved survival seen with perioperative chemotherapy with FLOT versus preoperative chemoradiotherapy<\/p>\n","protected":false},"author":6,"featured_media":119111,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[11],"class_list":["post-118993","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"_links":{"self":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/118993","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/comments?post=118993"}],"version-history":[{"count":0,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/118993\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media\/119111"}],"wp:attachment":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media?parent=118993"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/categories?post=118993"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/tags?post=118993"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}